LYEL Lyell Immunopharma Inc
Price (delayed)
$0.5075
Market cap
$149.83M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$1.31
Enterprise value
$93.54M
Highlights
Lyell Immunopharma's debt has decreased by 10% YoY
The net income has dropped by 68% since the previous quarter and by 46% year-on-year
The EPS has dropped by 66% since the previous quarter and by 41% year-on-year
Key stats
What are the main financial stats of LYEL
Market
Valuations
Earnings
Shares outstanding
295.23M
Market cap
$149.83M
Enterprise value
$93.54M
Price to earnings (P/E)
N/A
Price to book (P/B)
0.37
Price to sales (P/S)
2,175.43
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
1,533.37
Revenue
$61,000
Gross profit
$61,000
Operating income
-$358.76M
Net income
-$342.99M
EBIT
-$342.99M
EBITDA
-$323.36M
Free cash flow
-$162.86M
Per share
Balance sheet
Liquidity
EPS
-$1.31
EPS diluted
-$1.31
Free cash flow per share
-$0.62
Book value per share
$1.37
Revenue per share
$0
TBVPS
$1.88
Total assets
$490.86M
Total liabilities
$108.04M
Debt
$50.99M
Equity
$382.82M
Working capital
$325.81M
Debt to equity
0.13
Current ratio
7.06
Quick ratio
6.92
Net debt/EBITDA
0.17
Margins
Efficiency
Dividend
EBITDA margin
-530,103.3%
Gross margin
100%
Net margin
-562,285.2%
Operating margin
-588,123%
Return on assets
-55.8%
Return on equity
-65.9%
Return on invested capital
-66.9%
Return on capital employed
-78.5%
Return on sales
-562,285.2%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
LYEL stock price
How has the Lyell Immunopharma stock price performed over time
Intraday
4.79%
1 week
-9.02%
1 month
-28.6%
1 year
-75.6%
YTD
-20.7%
QTD
-5.67%
Financial performance
How have Lyell Immunopharma's revenue and profit performed over time
Revenue
$61,000
Gross profit
$61,000
Operating income
-$358.76M
Net income
-$342.99M
Gross margin
100%
Net margin
-562,285.2%
Lyell Immunopharma's net margin has shrunk by 74% QoQ
The operating margin has dropped by 71% since the previous quarter
The net income has dropped by 68% since the previous quarter and by 46% year-on-year
The operating income has dropped by 65% since the previous quarter and by 45% year-on-year
Growth
What is Lyell Immunopharma's growth rate over time
Valuation
What is Lyell Immunopharma stock price valuation
P/E
N/A
P/B
0.37
P/S
2,175.43
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
1,533.37
The EPS has dropped by 66% since the previous quarter and by 41% year-on-year
The stock's P/B is 50% less than its last 4 quarters average of 0.7
Lyell Immunopharma's equity has decreased by 42% YoY and by 28% from the previous quarter
LYEL's price to sales (P/S) is 65% less than its last 4 quarters average of 5888.4
The revenue has dropped by 53% year-on-year and by 3.2% since the previous quarter
Efficiency
How efficient is Lyell Immunopharma business performance
The ROE has plunged by 102% YoY and by 90% from the previous quarter
The ROA has dropped by 94% year-on-year and by 86% since the previous quarter
Lyell Immunopharma's ROIC has plunged by 88% from the previous quarter and by 85% YoY
The return on sales has dropped by 74% since the previous quarter
Dividends
What is LYEL's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for LYEL.
Financial health
How did Lyell Immunopharma financials performed over time
The current ratio has dropped by 56% year-on-year and by 47% since the previous quarter
LYEL's quick ratio has dropped by 56% year-on-year and by 47% since the previous quarter
Lyell Immunopharma's debt is 87% lower than its equity
The debt to equity is up by 44% year-on-year and by 30% since the previous quarter
Lyell Immunopharma's equity has decreased by 42% YoY and by 28% from the previous quarter
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.